Profile data is unavailable for this security.
About the company
Harbin Pharmaceutical Group Co is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Company’s main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.
- Revenue in CNY (TTM)15.31bn
- Net income in CNY598.45m
- Incorporated1991
- Employees10.06k
- LocationHarbin Pharmaceutical Group Co LtdNo. 7 Qunli Avenue, Daoli DistrictHAERBIN 150070ChinaCHN
- Phone+86 45 151870077
- Fax+86 45 151870077
- Websitehttps://www.hayao.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shenzhen Chipscreen Biosciences Co Ltd | 542.86m | 167.78m | 6.91bn | 1.05k | 40.00 | 3.96 | -- | 12.74 | 0.4203 | 0.4203 | 1.34 | 4.25 | 0.1842 | 1.90 | 4.80 | 519,478.90 | 4.24 | 1.49 | 4.87 | 1.71 | 90.53 | 94.98 | 23.03 | 7.50 | 3.03 | -- | 0.3684 | 0.00 | 23.11 | 36.83 | -20.37 | -6.20 | 24.68 | -- |
Chengdu Easton Biopharmaceuticals Co Ltd | 1.12bn | 244.74m | 6.97bn | 1.32k | 28.47 | 2.71 | -- | 6.21 | 2.04 | 2.04 | 9.35 | 21.41 | 0.361 | 1.64 | 8.03 | 848,603.90 | 7.87 | 10.13 | 9.60 | 12.39 | 79.12 | 86.87 | 21.80 | 18.64 | 2.91 | -- | 0.0763 | 21.87 | 14.43 | 19.70 | 6.06 | 30.81 | 71.28 | -- |
Beijing Foyou Pharma Co Ltd | 3.34bn | 486.79m | 7.13bn | 3.26k | 14.64 | 2.12 | -- | 2.14 | 1.01 | 1.01 | 6.95 | 6.99 | 0.7817 | 3.52 | 9.06 | 1,024,990.00 | 11.46 | -- | 14.81 | -- | 66.30 | -- | 14.66 | -- | 3.01 | -- | 0.0374 | -- | 14.18 | -- | 39.43 | -- | -- | -- |
Shenzhen Lifotronic Technology Co Ltd | 1.15bn | 328.58m | 7.38bn | 1.48k | 22.42 | 4.11 | -- | 6.44 | 0.769 | 0.769 | 2.68 | 4.20 | 0.5519 | 2.83 | 8.80 | 773,611.60 | 15.78 | 13.82 | 20.13 | 16.33 | 64.64 | 61.01 | 28.58 | 26.10 | 2.88 | -- | 0.1194 | 41.51 | 16.55 | 28.78 | 30.66 | 32.27 | -7.91 | -- |
Harbin Pharmaceutical Group Co., Ltd. | 15.31bn | 598.45m | 7.39bn | 10.06k | 11.99 | 1.59 | -- | 0.4825 | 0.2444 | 0.2444 | 6.27 | 1.84 | 1.14 | 6.45 | 3.40 | 1,521,468.00 | 4.91 | 0.6403 | 13.71 | 1.49 | 25.50 | 23.84 | 4.32 | 0.6682 | 1.03 | 22.94 | 0.3959 | 0.00 | 7.86 | 2.82 | 25.14 | 2.67 | -2.55 | -- |
JiangSu WuZhong Pharmactcl Devlpm Co Ltd | 2.15bn | -18.42m | 7.56bn | 1.01k | -- | 4.09 | -- | 3.52 | -0.0247 | -0.0247 | 2.97 | 2.59 | 0.5316 | 14.60 | 2.06 | 2,130,038.00 | -0.5042 | -3.88 | -1.01 | -6.68 | 26.64 | 30.38 | -0.9485 | -8.28 | 1.28 | 0.6243 | 0.492 | -- | 14.12 | -7.30 | -435.43 | -- | -31.67 | -- |
Vcanbio Cell & Gene Engineering Corp Ltd | 1.58bn | 130.95m | 7.61bn | 2.33k | 58.10 | 2.06 | -- | 4.81 | 0.2798 | 0.2798 | 3.38 | 7.90 | 0.2969 | 2.03 | 2.76 | 677,972.80 | 2.30 | 1.04 | 3.25 | 1.49 | 66.56 | 67.18 | 7.75 | 3.52 | 1.53 | -- | 0.0309 | 0.00 | 1.27 | 3.32 | -27.26 | 61.24 | 2.26 | -- |
Youcare Pharmaceutical Group Co Ltd | 4.00bn | 151.79m | 7.67bn | 3.19k | 50.55 | 2.13 | -- | 1.92 | 0.3373 | 0.3373 | 8.88 | 7.99 | 0.6805 | 2.18 | 3.96 | 1,253,963.00 | 2.65 | 8.25 | 3.94 | 15.07 | 59.07 | 63.81 | 3.89 | 8.51 | 1.30 | -- | 0.1794 | 53.50 | -8.53 | 10.96 | -38.57 | 15.70 | 39.08 | -- |
Guangxi Wuzhou Zhongheng Group Co Ltd | 2.99bn | 53.69m | 7.87bn | 3.36k | 143.85 | 1.19 | -- | 2.63 | 0.0159 | 0.0159 | 0.8701 | 1.92 | 0.2532 | 1.77 | 4.73 | 891,014.10 | -0.1899 | 3.69 | -0.2969 | 5.25 | 57.70 | 77.66 | -0.7501 | 10.68 | 2.58 | -- | 0.1819 | 42.74 | -14.17 | 5.79 | -74.25 | -33.44 | 2.52 | -30.12 |
Holder | Shares | % Held |
---|---|---|
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 31.39m | 1.25% |
The Vanguard Group, Inc.as of 29 Feb 2024 | 4.16m | 0.17% |
China Merchants Fund Management Co., Ltd.as of 30 Jun 2023 | 2.41m | 0.10% |
Maxwealth Fund Management Co., Ltd.as of 30 Jun 2023 | 1.88m | 0.08% |
Broad Fund Management Co. Ltd.as of 30 Jun 2023 | 1.63m | 0.07% |
Dimensional Fund Advisors LPas of 07 Mar 2024 | 1.28m | 0.05% |
Gfund Management Co., Ltd.as of 30 Jun 2023 | 1.10m | 0.04% |
Orient Fund Management Co., Ltd.as of 30 Jun 2023 | 1.00m | 0.04% |
Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2023 | 736.60k | 0.03% |
China Fund Management Co., Ltd.as of 30 Jun 2023 | 564.00k | 0.02% |